GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Clinical trials for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE explained in plain language.
Never miss a new study
Get alerted when new GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE trials appear
Sign up with your email to follow new studies for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for recurrent glioblastoma: experimental drug LMP744 enters human trials
Disease control Recruiting nowThis study tests a new drug called LMP744 in people whose glioblastoma has come back after standard treatment. The drug is designed to kill cancer cells by blocking a key growth signal and interfering with DNA repair. Participants will receive the drug through a vein for 5 days e…
Matched conditions: GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Disease control
Last updated Jul 02, 2026 04:00 UTC
-
Electric fields plus targeted radiation may boost survival in recurrent glioblastoma
Disease control Recruiting nowThis study is for adults with recurrent glioblastoma, an aggressive brain cancer. It tests whether adding a precise type of radiation (stereotactic radiosurgery guided by a special PET scan) to a device that delivers electric fields to the brain (TTFields) helps people live longe…
Matched conditions: GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Phase: NA • Sponsor: Prof. Franciszek Lukaszczyk Memorial Oncology Center • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New hope for brain cancer patients: experimental combo enters trials
Disease control Recruiting nowThis study tests a new drug (Debio 0123) combined with standard chemotherapy (temozolomide) and sometimes radiation in adults with glioblastoma, an aggressive brain cancer. The goal is to find the safest dose and see if the combination helps people live longer. About 116 particip…
Matched conditions: GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Phase: PHASE1, PHASE2 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC